Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - iTeos Therapeutics, Inc. | d892230dex211.htm |
| EX-10.3 - EX-10.3 - iTeos Therapeutics, Inc. | d892230dex103.htm |
| EX-10.1 - EX-10.1 - iTeos Therapeutics, Inc. | d892230dex101.htm |
| EX-4.1 - EX-4.1 - iTeos Therapeutics, Inc. | d892230dex41.htm |
| EX-3.3 - EX-3.3 - iTeos Therapeutics, Inc. | d892230dex33.htm |
| EX-3.1 - EX-3.1 - iTeos Therapeutics, Inc. | d892230dex31.htm |
| S-1 - S-1 - iTeos Therapeutics, Inc. | d892230ds1.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-1 of our report dated May 22, 2020, relating to the financial statements of iTeos Therapeutics, Inc. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises CVBA/SCRL
Zaventem, Belgium
June 24, 2020